Skip to main content
. 2022 Dec 8;87:104397. doi: 10.1016/j.ebiom.2022.104397

Fig. 7.

Fig. 7

Blocking EGFR-ERK1/2-MYC cascade sensitizes liver cancer cells to tigecycline in vivo. (a) Representative tumour images of each group in MHCC97H subcutaneous tumour model. (b) Tumour volumes of subcutaneous xenografts of control, tigecycline group, trametinib group, and their combined regimen group (n = 6). (c) Representative IHC images of MYC, HK2, LDHA, SHMT2 in xenografts tissues and H score analyses. (d) Representative tumour images of each group in immune-competent mice with mouse liver cancer cells (Hepa1-6) transplanted subcutaneously. (e) Tumour volumes of subcutaneous Hepa1-6 cells of control, tigecycline group, trametinib group, gefitinib group, tigecycline plus trametinib group, and tigecycline plus gefitinib group (n = 6). (f) Schematic outline of this study. Values are shown as mean ± SEM (Unpaired two-sided t-test).